Brigitte Dupriez

Lens, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.

Journal: Bone marrow transplantation
Published: December 04, 2020

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Journal: Blood advances
Published: September 18, 2020

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Journal: Haematologica
Published: September 22, 2017

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Journal: Haematologica
Published: July 12, 2017

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Journal: Genomics data
Published: March 23, 2015

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

Journal: Cancer research
Published: December 19, 2014

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Journal: Haematologica
Published: October 02, 2014

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Journal: Blood
Published: July 11, 2013

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Journal: British journal of haematology
Published: March 18, 2013

Improving survival trends in primary myelofibrosis: an international study.

Improving survival trends in primary myelofibrosis: an international study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 25, 2012

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Journal: Haematologica
Published: May 15, 2012

RBC-transfusion guidelines update.

RBC-transfusion guidelines update.

Journal: Leukemia research
Published: January 12, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026